FDAs New Commissioner Incentivizes Efficiency: Bonuses for Early Drug Approvals
The Food and Drug Administrations (FDA) new commissioner, Marty Makary, is introducing a pilot program offering bonuses to drug reviewers who complete their work ahead of schedule. This initiative, set to start as early as August, aims to reward efficiency in approving new medicines and vaccines. The bonuses will consider time saved by teams, along with work quality and complexity ratings. However, critics express concerns that this could lead to rushed safety checks and fuel perceptions of the FDA being too close to the industry. Makary has also implemented other speed-ups since taking office, such as one-month reviews for key national interest drugs and new paths for small patient trials. The FDA is under scrutiny for recent vaccine and therapy decisions, including rejections of experimental treatments followed by some reversals.
Support the show
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai
View sources & latest updates
https://sources.thednn.ai/5e506ef4be1c3997
